Granulocyte-Colony Stimulating Factor (G-CSF)-Induced Aortitis: A Case Report.
| Autor: | Ito M; Breast Surgery, Tohoku Kosai Hospital, Sendai, JPN., Amari M; Breast Surgery, Tohoku Kosai Hospital, Sendai, JPN., Sato A; Breast Surgery, Tohoku Kosai Hospital, Sendai, JPN., Hikichi M; Breast Surgery, Tohoku Kosai Hospital, Sendai, JPN. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2024 Feb 24; Vol. 16 (2), pp. e54845. Date of Electronic Publication: 2024 Feb 24 (Print Publication: 2024). |
| DOI: | 10.7759/cureus.54845 |
| Abstrakt: | Pegylated granulocyte colony-stimulating factor (G-CSF), commonly used in chemotherapy-induced neutropenia, has been associated with rare instances of aortitis. This study describes a 67-year-old female patient with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2-positive breast cancer, undergoing chemotherapy with an epirubicin/cyclophosphamide (EC) regimen (epirubicin, cyclophosphamide) and pegylated G-CSF for neutropenia prophylaxis. Post-treatment, she developed symptoms including intermittent fever and severe arthralgia. Laboratory tests revealed an elevated white blood cell count, C-reactive protein levels, and erythrocyte sedimentation rate, while a computed tomography scan showed thickening in the aortic arch and descending aorta. Given the clinical presentation and exclusion of other potential causes, pegylated G-CSF-induced aortitis was suspected. The patient's symptoms improved significantly following the cessation of pegylated G-CSF, aiding in the differentiation from other types of aortitis. This study highlights the importance of considering pegylated G-CSF as a potential cause of aortitis in patients presenting with unexplained symptoms of fever and inflammation after chemotherapy. The rapid improvement upon discontinuation of the drug is a key feature distinguishing it from other aortitis causes. In conclusion, while rare, aortitis should be considered in the differential diagnosis of patients treated with pegylated G-CSF who exhibit relevant clinical symptoms. Early detection and management, including the discontinuation of the causative agent, are crucial for patient recovery and prognosis. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Ito et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|